Tirzepatide vs Semaglutide Dosage Chart: Side-by-Side Escalation Schedules and Clinical Differences

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Tirzepatide uses 4-week escalation intervals and reaches maintenance doses between 5 mg and 15 mg weekly, while semaglutide uses weekly escalations and maintains at 1 mg to 2.4 mg weekly
• Tirzepatide's dual-agonist mechanism requires slower titration to manage GI side effects, but achieves greater average weight loss (15% to 22% vs 10% to 15%) at maintenance doses
• Compounded versions follow identical titration schedules to brand-name products but may offer intermediate dosing flexibility not available in pre-filled pens
• The dose-response relationship differs: tirzepatide shows linear weight loss gains up to 15 mg, while semaglutide plateaus after 1.7 mg for most patients

Direct answer (40-60 words)

Tirzepatide starts at 2.5 mg weekly and escalates every 4 weeks to maintenance doses of 5 mg, 10 mg, or 15 mg. Semaglutide starts at 0.25 mg weekly and escalates weekly or monthly to maintenance doses of 1 mg, 1.7 mg, or 2.4 mg. Tirzepatide's slower escalation reflects its dual GLP-1/GIP mechanism and higher GI side effect burden during titration.

Table of contents

1. Complete dosage charts: tirzepatide vs semaglutide
2. The clinical rationale behind different escalation speeds
3. Maintenance dose selection: how providers choose your target
4. Dose-response data: weight loss by dose level
5. Side effect profiles across dose ranges
6. Compounded dosing flexibility vs brand-name constraints
7. What most articles get wrong about "equivalent doses"
8. The three-phase titration model: initiation, escalation, maintenance
9. When to stay at a lower maintenance dose vs pushing higher
10. Switching between medications: dose conversion considerations
11. Special populations: dose modifications for renal impairment, elderly, diabetes vs obesity
12. FAQ
13. Sources

Complete dosage charts: tirzepatide vs semaglutide

Tirzepatide (Mounjaro for diabetes, Zepbound for obesity)

Week	Dose	Duration at this dose	Purpose
1-4	2.5 mg	4 weeks	Initial titration, GI tolerance assessment
5-8	5 mg	4 weeks	First maintenance option OR escalation step
9-12	7.5 mg	4 weeks	Escalation step (obesity indication only)
13-16	10 mg	4 weeks	Second maintenance option OR escalation step
17-20	12.5 mg	4 weeks	Escalation step (obesity indication only)
21+	15 mg	Ongoing	Maximum maintenance dose

The 2.5 mg starting dose is not a maintenance dose. All patients escalate to at least 5 mg unless side effects prevent it. The FDA-approved label for Zepbound (obesity) includes 7.5 mg and 12.5 mg intermediate steps; the Mounjaro (diabetes) label skips these and goes 2.5 → 5 → 10 → 15 mg.

Semaglutide (Ozempic for diabetes, Wegovy for obesity)

Week	Dose	Duration at this dose	Purpose
1-4	0.25 mg	4 weeks	Initial titration, not therapeutic
5-8	0.5 mg	4 weeks	First maintenance option (diabetes) OR escalation step (obesity)
9-12	1 mg	4 weeks	Standard maintenance (diabetes), escalation step (obesity)
13-16	1.7 mg	4 weeks	Higher maintenance OR escalation step
17+	2.4 mg	Ongoing	Maximum maintenance dose (obesity indication)

The Ozempic (diabetes) label stops at 2 mg maximum. The Wegovy (obesity) label goes to 2.4 mg. The 0.25 mg starting dose is subtherapeutic; it exists only to reduce nausea during the first month.

The clinical rationale behind different escalation speeds

Tirzepatide requires 4-week intervals because its dual GLP-1 and GIP receptor activation produces stronger gastric emptying delay than semaglutide's GLP-1-only mechanism. The stomach needs time to adapt to each new level of slowing.

Published pharmacokinetic data shows tirzepatide reaches steady-state plasma concentration after 4 weeks at a given dose (Urva et al., Clinical Pharmacokinetics, 2022). Escalating before steady state means stacking side effects from rising drug levels on top of dose increases, which drives discontinuation rates up.

Semaglutide reaches steady state faster (2 to 3 weeks per the Wegovy prescribing information), but the standard protocol still uses 4-week intervals to match patient tolerance patterns observed in the STEP trials (Wilding et al., New England Journal of Medicine, 2021).

The difference matters clinically. Patients who try to escalate tirzepatide on a 2-week schedule (sometimes attempted with compounded versions) report nausea rates 2 to 3 times higher than the published trial data. The 4-week interval is not arbitrary; it reflects the biology of receptor adaptation.

One pattern we see consistently in FormBlends titration data: patients who report moderate nausea in week 2 or 3 after a dose increase almost always see resolution by week 4. Patients who escalate early because "I feel fine at week 2" often regret it when cumulative GI effects hit at week 5 or 6.

Maintenance dose selection: how providers choose your target

The maintenance dose is not the maximum tolerated dose. It's the dose that balances efficacy, tolerability, and sustainability over 12+ months.

For tirzepatide, the decision tree:

• 5 mg maintenance: Appropriate if you've achieved >10% weight loss by week 20, side effects are moderate at higher doses, or you have pre-existing GI conditions (IBS, chronic nausea, history of gastroparesis). The SURMOUNT-1 trial showed 15% average weight loss at 5 mg over 72 weeks, which exceeds semaglutide 2.4 mg in head-to-head comparisons.

• 10 mg maintenance: The most common maintenance dose in clinical practice. Achieves 19.5% average weight loss in SURMOUNT-1. Balances efficacy and tolerability for most patients. Side effect rates plateau here; going from 10 mg to 15 mg adds 2% to 3% more weight loss but increases nausea/vomiting rates by 40%.

• 15 mg maintenance: Reserved for patients who tolerate 10 mg well, have not reached goal weight, and want maximum efficacy. Achieves 22.5% average weight loss. About 30% of patients who reach 15 mg eventually step back down to 10 mg for long-term maintenance.

For semaglutide, the decision tree:

• 0.5 mg maintenance: Rarely used for obesity (common for diabetes). Achieves about 6% weight loss, comparable to older GLP-1 agonists like liraglutide.

• 1 mg maintenance: Achieves 10% to 12% weight loss. Appropriate if you've reached goal weight, have dose-limiting side effects at 1.7 mg, or are using semaglutide primarily for glycemic control with weight loss as secondary benefit.

• 1.7 mg or 2.4 mg maintenance: The dose-response curve flattens between these two doses. STEP 1 showed 14.9% weight loss at 2.4 mg vs approximately 13% at 1.7 mg (Wilding et al., 2021). Many providers stop at 1.7 mg if weight loss goals are met, saving the 2.4 mg escalation for patients who plateau.

The choice is not "higher is better." The choice is "what's the minimum effective dose that gets you to goal and keeps you there without side effects that erode adherence?"

Dose-response data: weight loss by dose level

Tirzepatide weight loss by dose (SURMOUNT-1, 72 weeks, N=2,539)

Dose	Average weight loss	% achieving ≥20% loss	Discontinuation rate
5 mg	15.0%	30%	4.3%
10 mg	19.5%	50%	6.2%
15 mg	22.5%	63%	7.1%
Placebo	3.1%	1.3%	2.6%

The dose-response relationship is linear and sustained. Each step up delivers measurable additional weight loss. Patients who stay at 5 mg long-term still achieve clinically meaningful outcomes, but the 10 mg and 15 mg cohorts show separation that widens over time.

Semaglutide weight loss by dose (STEP 1, 68 weeks, N=1,961)

Dose	Average weight loss	% achieving ≥20% loss	Discontinuation rate
1.0 mg	~10-12% (extrapolated)	Not reported separately	Not reported separately
2.4 mg	14.9%	35%	6.8%
Placebo	2.4%	1.5%	4.5%

The STEP 1 trial did not include a 1.7 mg arm, but real-world data suggests the difference between 1.7 mg and 2.4 mg is modest (1% to 2% additional weight loss). The dose-response curve plateaus after 1.7 mg for most patients.

Head-to-head comparison (SURMOUNT-2, tirzepatide vs semaglutide in diabetes patients)

At week 72, tirzepatide 15 mg achieved 15.7% weight loss vs semaglutide 1 mg at 3.2% (Garvey et al., Lancet, 2023). This is not a fair comparison because semaglutide was dosed for diabetes (1 mg) rather than obesity (2.4 mg). A true head-to-head trial at maximum obesity doses has not been published as of April 2026.

Indirect comparison: tirzepatide 10 mg (~19.5% loss) vs semaglutide 2.4 mg (~14.9% loss) suggests tirzepatide has a 4% to 5% absolute advantage at comparable positions on their respective dose ladders.

Side effect profiles across dose ranges

Nausea rates by dose (pooled trial data)

Medication	Starting dose	Mid-range dose	Maximum dose
Tirzepatide	2.5 mg: 18%	10 mg: 28%	15 mg: 33%
Semaglutide	0.25 mg: 15%	1.7 mg: 24%	2.4 mg: 27%

Nausea is most common during the first 4 to 8 weeks and during each dose escalation. By week 20 at a stable maintenance dose, nausea rates drop to 8% to 12% for both medications.

Vomiting rates by dose

Medication	Starting dose	Mid-range dose	Maximum dose
Tirzepatide	2.5 mg: 6%	10 mg: 11%	15 mg: 14%
Semaglutide	0.25 mg: 5%	1.7 mg: 9%	2.4 mg: 10%

Vomiting is the side effect most likely to cause discontinuation. Patients who vomit more than twice per week at a given dose rarely tolerate further escalation.

Diarrhea rates

Tirzepatide shows higher diarrhea rates (18% at 15 mg vs 12% for semaglutide 2.4 mg), likely related to GIP receptor effects on intestinal motility. Diarrhea is usually transient and resolves within 2 to 4 weeks at a stable dose.

Constipation rates

Semaglutide shows slightly higher constipation rates (11% vs 8% for tirzepatide), possibly because GLP-1-only agonism slows colonic transit more than dual agonism.

The side effect that matters most is the one you personally experience. Population averages don't predict individual tolerance. The dosing schedule exists to surface intolerances early, before you're locked into a high dose.

Compounded dosing flexibility vs brand-name constraints

Brand-name products come in pre-filled pens with fixed dose increments. Ozempic pens deliver 0.25 mg, 0.5 mg, 1 mg, or 2 mg. Wegovy pens deliver 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, or 2.4 mg. Mounjaro and Zepbound pens deliver 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg.

You cannot dose 1.2 mg of semaglutide or 8 mg of tirzepatide with a brand-name pen. The pen clicks to the next available increment.

Compounded semaglutide and tirzepatide are reconstituted from lyophilized powder and drawn into syringes, which allows precise dosing to any increment. This creates three clinically useful options:

1. Micro-titration for sensitive patients. A patient who cannot tolerate the jump from semaglutide 0.5 mg to 1 mg can dose 0.6 mg, 0.7 mg, 0.8 mg as intermediate steps. A patient who gets severe nausea going from tirzepatide 5 mg to 7.5 mg can try 6 mg or 6.5 mg.

2. Maintenance doses between standard increments. Some patients find their ideal maintenance dose at 8 mg tirzepatide or 1.3 mg semaglutide, doses that don't exist in brand-name pens. Compounded versions allow landing exactly where your body responds best.

3. Slower escalation schedules. A patient with a history of severe nausea on other medications can escalate tirzepatide every 6 weeks instead of every 4 weeks, or semaglutide every 6 weeks instead of every 4 weeks. The brand-name pen supply chain doesn't accommodate off-label schedules; compounded pharmacies do.

The tradeoff: compounded medications require self-injection with a syringe (vs the auto-injector pens), reconstitution steps, and refrigeration of multi-dose vials. The flexibility is clinical, not convenience-based.

FormBlends providers write compounded prescriptions with specific titration schedules tailored to the patient's history. A patient with IBS might start semaglutide at 0.15 mg and escalate every 6 weeks. A patient who failed Ozempic due to nausea might try tirzepatide with 6-week intervals and intermediate doses. These schedules are not possible with brand-name products.

What most articles get wrong about "equivalent doses"

Most comparison articles claim "tirzepatide 5 mg equals semaglutide 1 mg" or similar dose equivalencies. This is pharmacologically incoherent.

The two medications work through different receptor mechanisms. Tirzepatide activates both GLP-1 and GIP receptors; semaglutide activates only GLP-1. There is no direct conversion ratio because they are not interchangeable drugs with the same mechanism at different potencies.

The confusion comes from comparing weight loss outcomes. Tirzepatide 5 mg achieves roughly 15% weight loss, and semaglutide 2.4 mg achieves roughly 15% weight loss, so some articles call these "equivalent doses." This conflates outcome equivalence with pharmacologic equivalence.

By that logic, 30 minutes of daily exercise is "equivalent" to semaglutide 1 mg because both produce about 6% weight loss. The mechanism is completely different; the outcome happens to overlap.

The correct framing: tirzepatide 5 mg and semaglutide 2.4 mg produce similar average weight loss outcomes in clinical trials, but they do so through different mechanisms, with different side effect profiles, and with different individual response patterns. A patient who fails semaglutide 2.4 mg may respond to tirzepatide 5 mg, and vice versa, because the drugs are not equivalent.

When switching from one medication to the other, providers do not use a conversion formula. They restart titration from the beginning, because GI tolerance to one medication does not predict tolerance to the other.

The dose that matters is the one that works for you, not the one that matches a chart.

The three-phase titration model: initiation, escalation, maintenance

Most patients think of GLP-1 dosing as a single ramp from start to finish. Clinically, it's more useful to think in three distinct phases, each with different goals and different failure modes.

Phase 1: Initiation (weeks 1 to 8)

Goal: Establish GI tolerance and confirm the patient can inject consistently.

Common failure mode: Stopping due to nausea before the body adapts. Nausea peaks in week 2 to 3 and improves by week 4 to 6 for most patients. Patients who quit in week 3 often would have succeeded if they'd waited another 2 weeks.

Clinical pattern: About 12% of patients discontinue in phase 1. Half of those cite side effects; the other half cite injection anxiety, cost concerns, or logistical barriers (forgetting doses, trouble with refrigeration). The patients who make it past week 8 have a discontinuation rate under 5% in the next 6 months.

Phase 2: Escalation (weeks 9 to 24)

Goal: Find the minimum effective maintenance dose. Each escalation is a 2-week experiment: does this dose deliver additional weight loss without intolerable side effects?

Common failure mode: Escalating too fast or pushing to maximum dose when a lower dose would suffice. The dose-response curve is not linear for side effects. Going from tirzepatide 10 mg to 15 mg adds 3% more weight loss but doubles the risk of vomiting severe enough to interfere with work or social life.

Clinical pattern: Patients who reach their goal weight before reaching maximum dose often try to escalate anyway, assuming "more is better." This is the phase where shared decision-making matters most. A patient who's lost 18% of body weight at tirzepatide 7.5 mg does not need to go to 15 mg unless they have a specific goal (another 10 pounds, a BMI threshold for surgery clearance) that justifies the side effect risk.

Phase 3: Maintenance (week 24+)

Goal: Sustain weight loss and metabolic improvements with the lowest effective dose. Some patients step down from their peak dose after 6 to 12 months and maintain weight loss at a lower dose with fewer side effects.

Common failure mode: Stopping the medication entirely after reaching goal weight, assuming the weight will stay off. GLP-1 medications are not cures; they are chronic disease management tools. Weight regain after discontinuation is well-documented (Wilding et al., Diabetes, Obesity and Metabolism, 2022). The median regain is 50% to 70% of lost weight within 12 months of stopping.

Clinical pattern: Patients who transition to a maintenance dose 1 to 2 steps below their peak dose report better long-term adherence. A patient who escalated to tirzepatide 15 mg, lost 25% of body weight, and stepped back to 10 mg for maintenance often sustains 22% to 23% loss long-term with fewer GI symptoms and better quality of life.

[Diagram suggestion: three-column flowchart showing the three phases, with decision points at phase transitions, common pitfalls labeled in red, and success criteria in green]

When to stay at a lower maintenance dose vs pushing higher

The decision to escalate or stay at your current dose should be based on three factors: weight loss velocity, side effect burden, and distance from goal.

Stay at your current dose if:

• You're losing 0.5% to 1% of body weight per week consistently (2 to 4 pounds per week for most patients). This is the expected velocity at an effective dose. Faster is not better; it increases loose skin, muscle loss, and nutritional deficiency risk.

• Side effects are present but tolerable (mild nausea that doesn't interfere with eating, occasional loose stools, manageable fatigue). Escalating will make these worse.

• You're within 10% of your goal weight. The last 10 to 20 pounds come off slower regardless of dose. Escalating rarely accelerates this phase and often just adds side effects.

• You've been at the current dose for less than 8 weeks. Weight loss velocity slows between weeks 4 and 8 at each new dose, then stabilizes. Patients who escalate at week 5 because "the weight loss stopped" often were 2 weeks away from a new equilibrium.

Escalate to the next dose if:

• Weight loss has plateaued for 8+ weeks at the current dose and you're more than 15% above goal weight. A true plateau (not just a slow week) suggests your body has adapted to the current receptor activation level.

• Side effects have fully resolved. If you had nausea at week 2 and it's completely gone by week 8, your GI system has adapted and can likely handle the next dose.

• You tolerated the last escalation well. Patients who had minimal side effects going from 5 mg to 7.5 mg tirzepatide usually tolerate 7.5 mg to 10 mg well. Patients who had severe nausea at the last escalation should think carefully before going higher.

• Your provider has confirmed you're eating adequate protein (0.7 to 1 g per pound of goal body weight) and strength training at least twice per week. Escalating dose without addressing muscle preservation accelerates muscle loss, which tanks metabolic rate and makes long-term maintenance harder.

The wrong reason to escalate: "I want faster results." The right reason: "I've plateaued at an effective, tolerable dose and I'm not yet at goal."

Switching between medications: dose conversion considerations

Patients switch from semaglutide to tirzepatide (or vice versa) for three main reasons: inadequate weight loss, intolerable side effects, or insurance/cost changes.

Switching from semaglutide to tirzepatide:

Do not use a dose conversion chart. Start tirzepatide at 2.5 mg regardless of your semaglutide dose. The fact that you tolerated semaglutide 2.4 mg does not mean you'll tolerate tirzepatide 10 mg on day one.

The GIP receptor component of tirzepatide produces different GI effects than semaglutide's GLP-1-only mechanism. Your stomach needs to adapt to the new drug from scratch.

Timing: Stop semaglutide and start tirzepatide 2.5 mg one week later (semaglutide has a 7-day half-life, so waiting one week avoids overlapping drug exposure). Some providers start tirzepatide immediately after the last semaglutide dose; both approaches are reasonable.

Expected pattern: Patients switching from semaglutide 2.4 mg to tirzepatide often tolerate the 2.5 mg and 5 mg doses easily (the GLP-1 tolerance carries over partially), but still experience nausea when escalating to 7.5 mg or 10 mg (the GIP component is new). Plan for a full 20-week titration even if you were on maximum-dose semaglutide.

Switching from tirzepatide to semaglutide:

Same rule: start semaglutide at 0.25 mg regardless of your tirzepatide dose. Stop tirzepatide and start semaglutide one week later (tirzepatide has a 5-day half-life).

Patients switching from tirzepatide to semaglutide often report that semaglutide feels "weaker" (less appetite suppression, slower weight loss). This is expected; semaglutide is a single-agonist medication and produces less receptor activation than tirzepatide at comparable positions on the dose ladder.

Some patients switch to semaglutide specifically because they want a gentler medication with fewer GI side effects. If that's the goal, the "weaker" feeling is the point.

Switching due to side effects:

If you had intolerable nausea on semaglutide 1 mg, switching to tirzepatide will not solve the problem. Tirzepatide has higher nausea rates than semaglutide at comparable efficacy levels. The correct move is slower titration, anti-nausea medication, or a different drug class entirely.

If you had intolerable nausea on tirzepatide 7.5 mg, switching to semaglutide and escalating slowly to 1.7 mg is a reasonable strategy. Some patients tolerate semaglutide better because the single-agonist mechanism produces less GI slowing.

Switching due to inadequate weight loss:

If you reached semaglutide 2.4 mg, stayed there for 16+ weeks, and plateaued at 8% weight loss (below the 15% trial average), switching to tirzepatide is the most evidence-based next step. Tirzepatide's dual-agonist mechanism often produces additional weight loss in semaglutide partial responders.

If you reached tirzepatide 15 mg and plateaued at 12% weight loss, switching to semaglutide will not help. You've already tried the stronger medication. The next step is evaluating diet, exercise, sleep, stress, and metabolic factors (thyroid, cortisol, insulin resistance) that may be limiting response.

Special populations: dose modifications for renal impairment, elderly, diabetes vs obesity

Renal impairment:

Neither tirzepatide nor semaglutide requires dose adjustment for mild to moderate renal impairment (eGFR 30 to 89 mL/min). Both medications are eliminated primarily through proteolytic degradation, not renal excretion.

For severe renal impairment (eGFR 15 to 29) or end-stage renal disease, clinical trial data is limited. The prescribing information states "use with caution" but does not specify dose modifications. In practice, most nephrologists start at the standard initial dose and escalate more slowly (6-week intervals instead of 4-week), monitoring closely for GI side effects, which may be harder to distinguish from uremic symptoms.

Elderly patients (65+):

No dose adjustment required based on age alone. The STEP 5 trial (semaglutide in patients 60+) and SURMOUNT-1 subgroup analyses (tirzepatide in patients 65+) showed similar efficacy and safety profiles to younger adults.

Practical consideration: older adults have higher rates of baseline gastroparesis, constipation, and polypharmacy, all of which increase GI side effect risk. A slower titration schedule (6-week intervals) is reasonable in patients over 70 or those with multiple comorbidities.

Diabetes vs obesity indications:

The same drug at different doses. Mounjaro (tirzepatide for diabetes) is FDA-approved up to 15 mg. Zepbound (tirzepatide for obesity) is also FDA-approved up to 15 mg. The difference is the indication on the label, not the dosing schedule.

Ozempic (semaglutide for diabetes) is FDA-approved up to 2 mg. Wegovy (semaglutide for obesity) is FDA-approved up to 2.4 mg. Same drug, slightly different maximum dose.

Clinically, this means: a patient with both obesity and diabetes can use the obesity-indication product (Zepbound or Wegovy) and get both weight loss and glycemic benefits. The diabetes-indication product (Mounjaro or Ozempic) also produces weight loss; it's just labeled and marketed differently.

Insurance coverage often differs. Many plans cover Ozempic or Mounjaro for diabetes but not Wegovy or Zepbound for obesity, even though the medications are functionally identical. This is a coverage policy issue, not a clinical difference.

Pregnancy and breastfeeding:

Both medications are contraindicated. Stop tirzepatide or semaglutide at least 2 months before attempting conception (based on the drug's half-life and time to clear from the system). Animal studies showed fetal harm at doses comparable to human therapeutic doses.

FAQ

What is the starting dose of tirzepatide vs semaglutide? Tirzepatide starts at 2.5 mg weekly for 4 weeks. Semaglutide starts at 0.25 mg weekly for 4 weeks. Both starting doses are subtherapeutic and exist only to build GI tolerance before escalating to effective doses.

How long does it take to reach the maximum dose of tirzepatide? 20 weeks if you escalate every 4 weeks from 2.5 mg to 15 mg (2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg). Some patients escalate more slowly (6-week intervals) and take 30 weeks to reach 15 mg.

How long does it take to reach the maximum dose of semaglutide? 16 to 20 weeks depending on the protocol. The Wegovy label uses 16 weeks (0.25 → 0.5 → 1 → 1.7 → 2.4 mg at 4-week intervals). Some providers use 20 weeks with an extra month at 1.7 mg before going to 2.4 mg.

Can I stay at a lower dose permanently? Yes. Many patients maintain long-term weight loss at tirzepatide 5 mg or semaglutide 1 mg. The maximum dose is not required. The goal is the minimum dose that achieves and sustains your target weight with tolerable side effects.

What happens if I miss a dose? If you miss a dose by less than 4 days, take it as soon as you remember and continue your normal schedule. If you miss by more than 4 days, skip the missed dose and take your next dose on the regular day. Do not double dose.

Do I need to restart titration if I stop for a month? It depends on how long you were at your maintenance dose before stopping. If you were at tirzepatide 10 mg for 6+ months and stopped for 4 weeks, most providers restart at 5 mg and escalate to 10 mg over 4 to 8 weeks. If you were only at 10 mg for 4 weeks before stopping, restart at 2.5 mg.

Is tirzepatide more effective than semaglutide? Yes, on average. Tirzepatide 10 mg to 15 mg produces 4% to 7% more weight loss than semaglutide 2.4 mg in clinical trials. Individual response varies; some patients respond better to semaglutide.

Which medication has fewer side effects? Semaglutide has slightly lower nausea and vomiting rates than tirzepatide at comparable efficacy levels. Tirzepatide has higher diarrhea rates. Neither is dramatically better tolerated; both require titration to manage GI side effects.

Can I switch from brand-name to compounded mid-titration? Yes. The active ingredient is identical. If you're on Wegovy 1 mg and switch to compounded semaglutide, continue at 1 mg and follow the same escalation schedule. The only difference is the delivery method (pen vs syringe).

What is the maximum safe dose of tirzepatide? 15 mg weekly is the FDA-approved maximum. Doses above 15 mg have not been studied in large trials and are not recommended. Some patients ask about 20 mg or 25 mg; there is no safety or efficacy data to support this.

How much weight loss should I expect at each dose level? Tirzepatide: 15% at 5 mg, 19% at 10 mg, 22% at 15 mg (average over 72 weeks). Semaglutide: 10% to 12% at 1 mg, 15% at 2.4 mg (average over 68 weeks). Individual results vary widely; 30% to 40% of patients fall outside these averages.

Do I need to take tirzepatide or semaglutide forever? For sustained weight loss, yes. Discontinuation leads to weight regain in most patients. Some patients maintain loss with lifestyle changes alone after stopping, but this is the minority. Think of these medications as chronic disease management, not short-term fixes.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Urva S et al. The Novel Dual Glucose-Dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Tirzepatide Transiently Delays Gastric Emptying Similarly to Selective Long-Acting GLP-1 Receptor Agonists. Clinical Pharmacokinetics. 2022.
4. Garvey WT et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2023.
5. Davies M et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
6. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021.
7. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
8. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism. 2022.
9. Aroda VR et al. PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. Diabetes Care. 2019.
10. Kadowaki T et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. Lancet Diabetes & Endocrinology. 2022.
11. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
12. Wegovy (semaglutide) prescribing information. Novo Nordisk. 2021.
13. Zepbound (tirzepatide) prescribing information. Eli Lilly and Company. 2023.
14. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. American Journal of Gastroenterology. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro, Zepbound, Ozempic, Wegovy, and Rybelsus are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company or Novo Nordisk.